Technology
Evaluation of tumor tissue is used for establishing a diagnosis as well as to determine status of therapeutically relevant biomarkers (gene variants, protein expression) which inform selection of targeted anti-cancer agents.
However, conventional molecular profiling assessments have a limited coverage of variants and each biomarker has to be evaluated in individual tests.
Advanced, deep molecular profiling of tumors can provide critical insight into the molecular and functional dynamics of the tumor which may not be revealed by conventional tumor assessments. A comprehensive molecular profiling test can identify multiple tumor vulnerabilities as well as resistance mechanisms in a single step. This information can be used by the treating physicians to select the most appropriate and effective treatment strategy with low risks of treatment failure as well as of toxicities associated with treatment failure.
About Celldx™
CellDx™ is an intensive and in-depth tumor molecular profiling. It analyses millions of data points at the molecular level to reveal threats and vulnerabilities which enable optimal identification of targets for precision treatment selection.
CellDx™ evaluates:
- Gene variants such as point mutations (SNV, Single-Nucleotide Variants), Insertions and Deletions, Translocations, Rearrangements and Fusions,
- Tumor Mutation Burden,
- Microsatellite instability,
- PDL1 status
CellDx™ is agnostic to classical determinants such as primary organ, histological subtype, morphology (grade), aggressiveness and extent of disease.
Reliable Technology
Clinical Performance
The clinical utility of CellDx™ for informing selection of patient-specific, safe and efficacious anti-cancer treatment regimens has been demonstrated in several clinical studies and case reports.
CellDx™ is available for all solid organ cancers.
CellDx™ can provide therapeutically relevant insight into the tumor, which can assist physicians to make life-saving clinical management decisions more effectively.